

JCWS/CS 22 SEP 2004

09/22/04 09:15 FAX 6123408856

DORSEY & WHITNEY LLP

001/005



FAX COVER SHEET

The information contained in this facsimile message, if a client of this firm is a named addressee, or the message is otherwise intended for a client, is presumptively legally privileged and confidential information. If you are not a named addressee, or if there is any reason to believe that you may have received this message in error, (1) do not read the message below; (2) do not distribute or copy this facsimile; and (3) please immediately call us collect at the number of the sender below.

DATE:	September 22, 2004	TOTAL # OF PAGES: (INCLUDING THIS COVER SHEET)	5
TO:	Office of Initial Patent Exam	FAX #:	1-703-748-9195
FIRM NAME:	U.S. Patent and Trademark Office	PHONE #:	1-703-308-1202
FROM:	Scott D. Rothenberger, Ph.D., Esq.	FAX #:	(612) 340-8856
PHONE #:	(612) 340-8819	EMAIL:	rothenberger.scott@dorsey.com

COMMENTS:

Attached please find:

Transmittal Letter (1 pg.);
Request for Corrected Filing Receipt (1 pg.);
Copy of Official Filing Receipt with Correction shown (2 pgs.);

First Name Inventor: Rajinder Singh
Client Name: Rigel Pharmaceuticals, Inc.
Application No.: 10/631,029
Filing Date: July 29, 2003
Application Title: Methods for Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds
Attorney/LA Initials: SDR/baa
Faxied: 22 September 2004
Our Dkt. No.: 28575/US/US

ORIGINAL WILL BE SENT VIA: MAIL E-MAIL MESSENGER AIR COURIER WILL NOT BE SENT

PLEASE CONTACT BARB A. AVERY AT (612) 492-6859 IF THIS TRANSMISSION IS INCOMPLETE OR CANNOT BE READ.

REFERENCE # 5088: 467802-451

DORSEY & WHITNEY LLP • WWW.DORSEY.COM • T 612.340.2600 • F 612.340.2668
SUITE 1500 • 50 SOUTH SIXTH STREET • MINNEAPOLIS, MINNESOTA 55402-1498
USA CANADA EUROPE ASIA

Docket: 28575/US/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor:	Rajinder Singh	
Application No.:	10/631,029	Examiner: Unknown
Filing Date:	July 29, 2003	Group Art Unit: 3731
Title:	Methods for Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds	

TRANSMITTAL LETTER

Office of Initial Patent Examination's
 Filing Receipt Corrections
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, Virginia 22313-1450

I hereby certify that this document is being sent via Facsimile under 37 C.F.R. 1.6(d) to: Office of Initial Patent Examination's Filing Receipt Corrections, 703.746.9195, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 22 day of September, 2004.

Barbara A. Avery
 Barbara A. Avery

Dear Sir:

The following documents are enclosed in connection with the above-referenced patent application:

1. Request For Corrected Filing Receipt (1 pg.); and
2. Copy of Filing Receipt with Correction Marked (2 pgs.).

Respectfully submitted,

DORSEY & WHITNEY LLP
 Customer Number 25763

Date: September 22, 2004

By: *Scott D. Rothenberger*
 Scott D. Rothenberger
 Reg. No. 41,277
 Intellectual Property Department
 Suite 1500
 50 South Sixth Street
 Minneapolis, MN 55402-1498
 (612) 340-8819

Docket: 28575/US/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor:	Rajinder Singh		
Appln. No.:	10/631,029		
Filing Date:	July 29, 2003	Examiner:	Unknown
Title:	<u>Methods for Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds</u>	Group Art Unit:	1632

REQUEST FOR CORRECTED FILING RECEIPT

Office of Initial Patent Examination's
Filing Receipt Corrections
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

I hereby certify that this document is being sent via Facsimile under 37 C.F.R. 1.6(d) to: Office of Initial Patent Examination's Filing Receipt Corrections, 703.746.9195, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 22 day of September, 2004.

Barbara A. Avery
Barbara A. Avery

Dear Sir:

Please correct the filing receipt in the above-identified application as follows:

Under the heading TITLE:

The ninth word of the Title is incorrect:

The Title reads, "Methods for treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds" and should read -- Methods for treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds --.

The Title is correct on the first page of the Specification and on the Utility Patent Application Transmittal.

It is believed that no fees are due in connection with this request. However, the Office is authorized to charge any deficiency in fees associated with this request to Deposit Account 04-1420.

Respectfully submitted,

DORSEY & WHITNEY LLP
Customer Number 25763

By: Scott D. Rothenberger
Scott D. Rothenberger
Reg. No. 41,277
Intellectual Property Department
Suite 1500
50 South Sixth Street
Minneapolis, MN 55402-1498
(612) 340-8819

Date: September 22, 2004

UNITED STATES PATENT AND TRADEMARK OFFICE *Paged*

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Attn: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (o) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/631,029	07/29/2003	1632	0.00	28575/US/US	19	49	1

CONFIRMATION NO. 3056

Scott D. Rothenberger
 DORSEY & WHITNEY LLP
 Intellectual Property Department
 50 South Sixth Street, Suite 1500
 Minneapolis, MN 55402-1498

Sect 1.3.2004

FILING RECEIPT



--OC000000013694018*

Date Mailed: 09/01/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Rajinder Singh, Belmont, CA;
 Ankush Argade, Foster City, CA;
 Donald G. Payan, Hillsborough, CA;
 Jeffrey Clough, Redwood City, CA;
 Holger Keim, Menlo Park, CA;
 Somasekhar Bhamidipati, Foster City, CA;
 Catherine Sylvain, Burlingame, CA;
 Hui Li, Milbrae, CA;

Power of Attorney: The patent practitioners associated with Customer Number 25763.

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/399,673 07/29/2002
 and claims benefit of 60/443,949 01/31/2003
 and claims benefit of 60/452,339 03/06/2003

Foreign Applications

If Required, Foreign Filing License Granted: 08/31/2004

The number of your priority application, to be used for filing abroad under the Paris Convention is,
US10/631,029

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ****

Title

Methods for treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
pyrimidinedicmine

Preliminary Class

514

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).